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Abstract
Background: Although insulin therapy is well-accepted by symptomatic diabetic patients, it is still
often delayed in less severe patients, in whom injectable insulin remains under-used. A better
understanding of patients' perception of insulin would eventually help physicians to adopt the most
appropriate dialogue when having to motivate patients to initiate or to intensify insulin injection.
Methods: The 'Studying the Hurdles of Insulin Prescription' (SHIP) questionnaire was developed
based on a list of concepts derived from three diabetic patients' focus groups, and was included into
two cross-sectional studies with similar design: SHIP Oral study and SHIP Premix study. Diabetic
patients treated with oral hypoglycaemic agents (OHA; n = 1,494) and patients already treated with
insulin (n = 1,150) completed the questionnaire at baseline, 6- and 12 months. Psychometric
properties were assessed: 1) structure analysis by Principal Component Analysis (PCA) with
Varimax rotation, 2) internal consistency reliability (Cronbach's alpha), and 3) concurrent validity
(Spearman correlation coefficients with the Fear of Self-Injecting (FSI) score of the Diabetes Fear
of Injecting and Self-testing Questionnaire. Reluctance/motivation towards insulin was assessed.
Scores' ability to predict patients' insulin injection reluctance/motivation and initiation/
intensification was evaluated with the Area Under the Receiver Operating Characteristic (ROC)
Curve (AUC).
Results:  PCA analysis confirmed the structure of the 14 items grouped into 3 dimensions:
'acceptance and motivation', 'fear and constraints', and 'restraints and barriers' towards insulin
injection. Internal consistency reliability was excellent (Cronbach's alpha > 0.70); concurrent
validity was good. The three scores were significantly predictive of patients' reluctance/motivation
towards insulin injection initiation, as they were of patients' actual switch, except for the 'restraints
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and barriers' dimension. 'Acceptance and motivation' and 'fears and constraints' dimensions were
also significantly predictive of patients' reluctance/motivation towards insulin intensification. By the
end of the 12-month study, 179 of the initially OHA-treated patients had started insulin injections;
186 of the patients already treated with insulin had increased their injections.
Conclusion: The SHIP questionnaire provides reliable and valid assessment of diabetic patients'
attitude towards insulin and injections. The predictive power of scores for patients' reluctance/
motivation and actual treatment decisions demonstrates encouraging potential for further
application in clinical practice.
Background
Diabetes constitutes a major healthcare problem world-
wide. It is a highly prevalent disease, still increasing due to
population aging and growth, together with rising obesity
and physical inactivity [1,2]. Most patients have type 2
diabetes with poor control level, leading to increased
morbidity and mortality rates caused by complications
[3]. The economic burden of diabetes is highly significant,
due to direct medical costs along with indirect costs
related to a loss of productivity and the chronic aspect of
the disease [4-6]. There is increasing evidence showing
that improved blood glucose control decreases diabetic
complications [7-9]. Specifically, it has been reported that
improved blood glucose control with insulin or sulfony-
lurea therapy decreased the progression of microvascular
complications in patients with type 2 diabetes [10].
Oral anti-diabetic therapy is the most commonly used
treatment for type 2 diabetes, but its long-term efficacy is
limited. Despite being well-accepted by symptomatic dia-
betes patients, insulin therapy is still often delayed in less
severe patients, and is rarely used as an alternative treat-
ment [6,10-13]. Given the benefits of intensive therapy
combining oral anti-diabetic drugs plus insulin, this delay
and low acceptance for insulin therapy is concerning.
According to Brunton et al., both provider and patient fear
is one contributing factor, with insulin therapy viewed as
a "last resort" treatment option for severe disease [14].
Patients delay insulin therapy because of the lack of obvi-
ous symptoms at the beginning of the disease, and
because of physicians' fears about reducing the quality of
life of patients when starting insulin [15]. This may in turn
have important negative impacts on patients' well-being
[16]. Yet, a two-year prospective descriptive study showed
that insulin therapy initiation in relatively asymptomatic
type 2 diabetes patients who were treated with diet and/or
hypoglycaemic agents resulted in improved glycaemia
control, without major adverse influences on patients'
quality of life [15]. A recent randomised controlled trial
reported that patients who were offered inhaled insulin
opted more frequently for a treatment that included insu-
lin than patients in the control group who were offered
standard treatments [17].
Questionnaires exist that assess perceptions of diabetes
patients regarding insulin therapy. Amongst them, the
Insulin Delivery System Rating Questionnaire (IDSRQ)
and the Insulin-Therapy-Related Quality of Life question-
naire (ITR-QoL) are specifically designed to measure
patients' satisfaction with insulin delivery systems and/or
their preference [18,19]; others, such as the Diabetes
Treatment Satisfaction Questionnaire (DTSQ), the Insulin
Treatment Satisfaction Questionnaire (ITSQ) and the
triad of measures (i.e. Satisfaction Measure, Symptom
Measure and Productivity Measure) proposed by Brod
and colleagues aim at assessing patients' satisfaction with
insulin treatment regimen [20-22]. Cappelleri et al. high-
lighted the contribution of treatment convenience and
ease of use and social comfort as significant factors in dia-
betes patients' satisfaction [23]; recent studies from Brod
and al. identified several factors (e.g. age, co-morbidity,
treatment efficacy, weight gain) as contributing to
patients' satisfaction [24], and suggested that satisfaction
is not a static concept [25]. But so far, there is no question-
naire allowing the elicitation of patients' expectation and
attitude towards insulin therapy, as well as predicting
patients' intentions regarding insulin therapy. A better
understanding of the reasons why patients so poorly
accept insulin injection therapy would allow physicians to
adopt the most appropriate behaviour and dialogue when
having to motivate patients to initiate subcutaneous insu-
lin injections or to intensify the number of insulin injec-
tions.
In this paper, we present the development and psycho-
metric validation of a new self-administered instrument,
the Studying the Hurdles of Insulin Prescription (SHIP©)
questionnaire. The questionnaire aims at exploring moti-
vation, fears, and barriers towards insulin injection ther-
apy (type 2 diabetes patients treated with oral
hypoglycaemic agents) or towards intensifying injections
(type 1 or type 2 diabetic patients already treated with
insulin injection). The ability of the questionnaire to pre-
dict patients' intentions regarding initiating or intensify-
ing their insulin treatment, either as an injection or an
inhalation, was evaluated.Health and Quality of Life Outcomes 2007, 5:53 http://www.hqlo.com/content/5/1/53
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Methods
Development of the SHIP© questionnaire
This qualitative phase led to the item generation and
development of the pilot questionnaire. The overview of
the phase is represented in Figure 1. First, three focus
groups of type 1 and type 2 diabetes patients were used to
capture fears, constraints and benefits regarding insulin
therapy, insulin injections and insulin regimen step-up
[26]. A list of detailed concepts was established from
patients' own words, from which a test questionnaire was
developed and validated by the Advisory Committee (AC)
consisting of three diabetes specialists/endocrinologists,
one psychiatrist and two general practitioners. The word-
ing of the questionnaire was adapted to assess either the
attitude of patients currently treated with oral hypoglycae-
mic agents (OHA) regarding a switch to insulin therapy,
or the attitude of patients already treated with premix
insulin regarding a step-up in the number of insulin injec-
tion. The item content of the SHIP© questionnaire is pre-
sented in Table 1. Its content validity was assessed twice,
using patient cognitive debriefing among type 1 and type
2 diabetes patients [27]. The resulting pilot questionnaire
was validated by the AC.
Study design and patient populations
The pilot SHIP© questionnaire was administered in two
French multicentre cross-sectional studies conducted in
parallel, with identical design but different populations of
patients.
SHIP Oral Study
Four hundred and twelve random general practitioners
included about 1,500 ambulatory type 2 diabetes patients
treated with at least two OHAs. Pregnant women and type
1 diabetes patients were excluded from the study. Type 2
diabetes patients treated with no or only one OHA, and
those whose regimen added insulin were also excluded.
SHIP Premix study
Three hundred random diabetologists and endocrinolo-
gists included about 1,500 type 1 and type 2 diabetes
patients treated with two daily injections of Premix insu-
lin. Type 2 patients treated with OHAs only or with insu-
lin other than two premix injections were excluded from
the study.
For both studies, patients self-completed the SHIP© ques-
tionnaire at their first inclusion visit, at their physicians'
practice. In order to assess the proportion of patients pre-
senting symptoms of fear of injections, they were also
asked to complete the Diabetes Fear of Injecting and Self-
testing Questionnaire (D-FISQ) at baseline [28]. In paral-
lel, patients had to fill out a record card for blood glucose
control and hypoglycaemic treatment at the 6- and 12-
month follow-up visits. At each of the visits, patients who
did indeed start insulin injection treatment and those
who intensified the number of injections were counted.
Each of the two populations was randomly divided into
two subgroups based on a 2:1 ratio. One subgroup (two
thirds of the total population) was used for the finalisa-
tion step (to shorten the pilot questionnaires and to
define the process of scoring) and will be referred to as the
'finalisation dataset'; the second subgroup (one third of
the total population) was used for the validation step, and
will be referred to as the 'validation dataset'. Psychometric
properties were defined with the corresponding cross-sec-
tional populations of the two studies.
Statistical analysis
Principal Components Analysis (PCA) with Varimax
Rotation was used to assess the SHIP© questionnaire struc-
ture in each study. Floor and ceiling effects were exam-
ined, and psychometric properties were further assessed.
This included a Multitrait Analysis (MA) that evaluated
the final structure of the questionnaire by describing item
Overview of the qualitative phase of SHIP© questionnaire  development Figure 1
Overview of the qualitative phase of SHIP© questionnaire 
development.
3 focus groups
3 focus groups 
23 type 1 and type 2 diabetes patients 
Elaboration list of concepts: 
11 general concepts and 31 detailed concepts
Development of the SHIP
© questionnaire 
based on patients’ verbatim from  
SHIP Oral and SHIP Premix studies: 
First version = 22 items
First cognitive debriefing 
16 other patients type 1 and type 2 
Advisory Committee validation
Second version of the SHIP
© questionnaire: 
23 items 
Advisory Committee validation
Second cognitive debriefing 
16 other patients type 1 and type 2 
Advisory Committee validation
Final pilot version of the SHIP
© questionnaire:
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Table 1: Item contents of the SHIP© questionnaire and Pearson correlation coefficients between items and dimensions performed with 
cross-sectional populations at baseline for SHIP Oral and SHIP Premix studies. Correlations > 0.40 are in bold
Item 
contents
SHIP Oral Study (n = 1,478a) SHIP Premix Study (n = 1,130b)
Missing 
Data N (%)
Acceptance 
Motivation
Fears 
Constraints
Restraints 
Barriers
Missing 
Data N (%)
Acceptance 
Motivation
Fears 
Constraints
Restraints 
Barriers
Willingness 
because of 
more 
balanced 
diabetes
12 (0.80) 0.64 0.20 0.20 21 (1.83) 0.63 0.23 0.13
Happy 
because of 
improvement 
in quality of 
living
11 (0.74) 0.63 0.23 0.15 20 (1.74) 0.62 0.23 0.06
Favourable 
because of 
easiness to 
use of 
treatment
14 (0.94) 0.64 0.31 0.27 20 (1.74) 0.68 0.32 0.23
Advantage 
because of a 
less 
restrictive 
diet
NAc 0.57 0.12 0.11 20 (1.74) 0.50 0.08 -0.02
Confidence in 
physicians
23 (1.54) 0.55 0.11 0.24 20 (1.74) 0.56 0.17 0.18
Feeling 
restricted 
because of 
self-
surveillance
18 (1.20) 0.23 0.63 0.32 13 (1.13) 0.28 0.67 0.35
Constraint 
because of 
dependency, 
liberty loss
17 (1.14) 0.21 0.63 0.26 22 (1.91) 0.21 0.62 0.30
Upset 
diabetes is 
getting worse
15 (1.00) 0.04 0.41 0.21 22 (1.91) 0.07 0.47 0.25
Fear of having 
more 
hypoglycaemi
a crises
15 (1.00) 0.11 0.45 0.37 22 (1.91) 0.08 0.48 0.23
Fear that 
treatment 
gets more 
complicated
15 (1.00) 0.35 0.58 0.41 18 (1.57) 0.38 0.60 0.42
Bothered by 
being seen 
while injecting 
insulin
21 (1.41) 0.24 0.35 0.71 17 (1.48) 0.10 0.30 0.61
Fear that 
people notice 
I'm diabetic
16 (1.07) 0.17 0.34 0.57 19 (1.65) 0.08 0.34 0.57
Bothered by 
skin being 
marked at 
injection site
12 (0.80) 0.13 0.29 0.56 14 (1.22) 0.12 0.28 0.47
Stressed 
because 
injections can 
be painful
14 (0.94) 0.24 0.39 0.53 20 (1.74) 0.14 0.35 0.48
a 1,478 = 1,487-9, due to missing data
b 1,130 = 1,141-11, due to missing data
c NA, not assessedHealth and Quality of Life Outcomes 2007, 5:53 http://www.hqlo.com/content/5/1/53
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convergent validity and item discriminant validity [29].
Convergent validity was confirmed when correlations
between each item and its own scale were ≥ 0.40 [30].
Internal consistency reliability was determined using
Cronbach's alpha coefficient [31], values greater than 0.70
indicating a high level of internal consistency [32]. Con-
current validity was evaluated between the Fear of Self-
Injecting (FSI) score of the D-FISQ and the SHIP© ques-
tionnaire by calculating Spearman correlation coefficients
[28]. Correlation coefficients ranging between 0.4 and 0.7
were considered as reflecting similar but no redundant
concepts [33]. The discriminative power of the question-
naire was established by comparing groups of patients
based on age, gender, type of diabetes, time since patients'
diabetes had been diagnosed, HbA1c dosage, and the
number of times physicians have talked about insulin
therapy with their patients.
Descriptive analyses were completed by comparative tests
(Mann-Whitney Wilcoxon and Kruskal-Wallis tests) for
qualitative parameters, and by Spearman coefficient cor-
relations for quantitative parameters.
The ability of the SHIP© questionnaire to predict actual
change in patients' treatment regimen (initiation or inten-
sification of insulin injections), as well as patients' inten-
tion (reluctance-motivation) to initiate or to increase
insulin injections or inhaled insulin at the end of their
inclusion visit, at 6 months and at 12 months was pre-
dicted by performing three univariate logistic regressions
with each of the scores as a covariate. The predictive valid-
ity was determined by measuring the Area Under the
Receiver Operating Characteristic (ROC) Curve (AUC)
[34]. AUC was considered acceptable when higher than
0.70. First, univariate logistic regressions were realised in
the 'finalisation dataset' in order to define the AUC for
each of the items. Then, univariate logistic regressions
were performed in the 'validation dataset', on the final
questionnaire, in order to assess the predictive ability of
each dimension. For the intention regarding injected or
inhaled insulin items, patient responses were divided into
two groups: one containing the two negative modalities
("I would refuse" and "I would be rather reluctant",
respectively), and the other containing the two positive
modalities ("I would be quite motivated" and "I would be
highly motivated").
Statistical analyses were performed using Statistical Anal-
ysis Software version 8.02 for Windows. The significance
level of the tests was fixed at 0.05.
Results
Development of the SHIP© questionnaire
Eleven global concepts covering insulin therapy (benefits;
symbolic meaning; fears; constraints; products' character-
istics), insulin injections (symbolic meaning; fears; con-
straints; advantages), and intensification of insulin
injections (symbolic meaning; fears), divided into 31
detailed concepts were identified from the focus groups.
Based on these concepts, 22 items were designed, com-
prising 20 items related to the insulin regimen initiation/
intensification and two items related to inhaled insulin.
Following the first cognitive debriefing, one item was
added and the response choices were significantly modi-
fied in order to facilitate the understanding of the ques-
tionnaire by patients. Following the second cognitive
debriefing, two items were deleted. Finally, the SHIP©
questionnaire was constituted of 21 items: 18 items eval-
uated patient attitude towards initiation (SHIP Oral
study) or intensification (SHIP Premix study) of insulin
injections; one item asked patients to select 5 items they
found the most important out of the 18 previously
answered; one item assessed patient intentions regarding
either initiation or intensification of insulin injections;
one item covered patient intentions regarding inhaled
insulin if available. The structure of the questionnaire and
item content were identical in both studies. However, the
items' formulation slightly differed to fit patients' actual
treatment; precisely, the word "initiation" was used in the
SHIP Oral study versus "intensification" in the SHIP
Premix study.
Study population
Among the 1,494 type 2 patients (SHIP Oral study) and
the 1,150 type 1 and type 2 patients (SHIP Premix study)
recruited, respectively 1,487 (99.5%) and 1,141 (99.2%)
questionnaires were assessable (i.e. completed with less
than 50% missing data).
The number and percentages of missing data according to
the items of the questionnaire are summarised in Table 1.
Percentages of missing data ranged from 0.60 to 1.54 for
SHIP Oral, and from 1.13% to 3.91% for SHIP Premix.
Concerning patients included in SHIP Oral and SHIP
Premix studies, the overall mean ages were 63.9 years and
62.0 years, respectively; the proportions of male patients
were 57% and 52%; on average, patients had been diag-
nosed 10 and 16 years ago; mean body mass index (BMI)
was 30 kg/m2 and 29 kg/m2. The majority of patients
(75.2%) recruited for the SHIP Premix study had type 2
diabetes and had been treated with insulin for five years
on average. Thirty six percent of patients from the SHIP
Oral and 57% from the SHIP Premix studies had compli-
cations associated with their diabetes. Mean HbA1c at
inclusion was respectively 7.4% and 7.9%.Health and Quality of Life Outcomes 2007, 5:53 http://www.hqlo.com/content/5/1/53
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Patients' intentions and actual changes in treatment 
regimen
As observed from the responses of patients treated with
OHA to the questionnaire's item at the inclusion visit, the
majority of patients (70%) would be "rather reluctant" to
"reluctant" to start insulin injection; only 1.6% indeed
started it at the end of their inclusion visit. A large major-
ity of patients (83%) would have been "quite motivated"
to "highly motivated" to initiate an insulin treatment if
inhaled. Ninety-six percent of patients who were favoura-
ble to injected insulin were also favourable to inhaled
insulin. Concerning the SHIP Premix study, 63% of
patients were "quite motivated" to "highly motivated" to
increase the number of insulin injections. Again, a large
majority of patients (81%) would have been motivated to
increase their insulin therapy treatment if inhaled insulin
was available. At the end of their inclusion visit, 40% of
these patients had a change in their insulin treatment, but
only 13% corresponded to an increased number of injec-
tions.
Of all patients treated with OHA (n = 1,487), only 24 did
indeed initiate insulin injections at baseline. At the 6-
month follow-up visit, 98 additional patients joined the
group of patients already injecting insulin, and 57 addi-
tional patients initiated insulin injections at the 12-
month follow-up visit, thus resulting in a total of 179
patients (12% of the total cross-sectional population)
having started insulin injections by the end of the 12-
month study. 1,043 patients were reluctant to initiate an
insulin treatment by injection, and 247 to initiate inhaled
insulin therapy. Of patients already treated by insulin
injection (n = 1,141), 143 increased their number of injec-
tions at the end of the inclusion visit; at the 6-month visit,
25 decreased the number of injections, while 70 addi-
tional patients increased them, resulting in 188 patients
having increased the number of injections. Of these 188
patients, 67 patients increased the number of injections
and 69 decreased them at the 12-month visit, thus result-
ing in a total of 186 patients (corresponding to 16% of the
cross-sectional population) with an increased number of
insulin injections by the end of the 12-month study. At
this point, 427 patients were reluctant to increase the
number of insulin injections and 198 were reluctant to
increase their treatment even with inhaled insulin.
Finalisation of the SHIP© questionnaire: item reduction
The finalisation of the questionnaire was performed on
the 'finalisation dataset' (n = 992 for the SHIP Oral study
and n = 761 for the SHIP Premix study).
Based on a first PCA analysis with Varimax Rotation and
MA that were performed separately on the questionnaire
filled out at baseline, four items were eliminated as they
displayed poor discriminant or convergent validity, had
low predictive value, or were not adapted to patients
under insulin therapy without OHA. Three factors com-
prising 14 items were identified from the PCA analysis:
the first factor corresponded to items about patients'
acceptance and motivation for insulin; the second factor
contained items about patients' fears and constraints
regarding insulin therapy; the third factor contained items
about restraints and barriers patients perceived with insu-
lin therapy.
Validation of the SHIP© questionnaire: scoring
In order to validate the new structure of the questionnaire,
second PCA and MA analyses were performed with the
'validation dataset'. The three factors and 14 items were
confirmed, dealing with either insulin injection initiation
(SHIP Oral study) or insulin injection intensification
(SHIP Premix study). The three dimensions of the ques-
tionnaire were thus named respectively 1) 'acceptance and
motivation', 2) 'fears and constraints' and 3) 'restraints
and barriers' towards injection (Table 1).
Scoring of the SHIP© questionnaire was based on the
standardised sum of the items within one dimension, giv-
ing a range from 0 (lowest level for the dimension
assessed) to 100 (highest level). The distribution of SHIP©
questionnaire scores from both SHIP Oral and SHIP
Premix studies are shown in Table 2.
Instrument psychometric properties
Construct validity
The final structure of the SHIP© questionnaire was tested
by performing PCA analysis followed by MA, which vali-
dated the division of the questionnaire into three dimen-
sions. Item-dimension correlations were determined
(Table 1). Correlations of each of the items with its own
dimension were all higher than the threshold value of ≥
0.40. All items also satisfied the divergent validity criteria.
Internal consistency reliability
Table 3 summarises the data of the SHIP© questionnaire
completed by patients of the two cross-sectional studies at
baseline. Cronbach's alpha coefficients were good and
similar, ranging from 0.77 to 0.82 for the SHIP Oral study,
and 0.74 to 0.81 for the SHIP Premix study.
Concurrent validity
The correlation between the FSI score and the 'acceptance
and motivation' dimension score of SHIP Premix was the
weakest (Spearman coefficient = -0.18); correlation was
higher and similar between FSI score and 'fears and con-
straints' and 'restraints and barriers' dimension scores in
both studies (Spearman coefficients = 0.41 and 0.42,
respectively).Health and Quality of Life Outcomes 2007, 5:53 http://www.hqlo.com/content/5/1/53
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Predictive power of the SHIP© questionnaire scores
Figures 2A and 2B represent the ROC curves drawn to pre-
dict patients' intentions regarding insulin initiation and
actual change in treatment regimen for each dimension
score at baseline. AUCs are summarised in Table 4. In the
SHIP Oral study, AUC values of the 'acceptance and moti-
vation' dimension and to a lesser extent, the 'fears and
constraints' dimension, were the highest for predicting cli-
nicians' decisions about insulin injection initiation and
patients' intentions regarding insulin injection treatment
at baseline. These values were lower than 0.70 at 6- and
12-month follow-up visits. Value of the 'restraints and
barriers' dimension for predicting clinicians' decisions
about insulin injection initiation was low at baseline, and
slightly higher for predicting patients' reluctance to initi-
ate insulin injection (0.62 and 0.72, respectively). Values
to predict patients' reluctance regarding initiation of
inhaled insulin were lower than 0.70 for all three dimen-
sions.
In the SHIP Premix study, AUCs of the three dimensions
were all lower than 0.70, ranging from 0.58 to 0.65, for
assessing patients' switch to injection intensification at
baseline and the two follow-up visits (Figures 3A and 3B
and Table 4). Only the 'acceptance and motivation' and
'fears and constraints' dimensions showed fair ability to
predict patients' intentions regarding insulin intensifica-
tion, and the 'acceptance and motivation' dimension to
predict attitude towards intensification if inhaled insulin
was available.
Scores of the SHIP© questionnaire according to specific subgroups
In the SHIP Oral study, the 'acceptance and motivation'
score was significantly higher in men than in women
(scores = 49 and 45, respectively; p = 0.013) and in
younger people (p = 0.006), with scores decreasing in
older subjects. On the contrary, 'fears and constraints'
towards insulin therapy scores were significantly higher in
women and increased significantly in older subjects.
'Restraints and barriers' scores were significantly higher in
women and decreased in older patients. The 'acceptance
and motivation' score was significantly higher in patients
ROC Curve of the three scores about patients' attitude  towards initiating insulin injection (A) and their intentions  regarding insulin therapy (B) at baseline; ability of the ques- tionnaire to predict type 2 diabetes patients' attitude and  intentions regarding initiating insulin injection are deduced  from the Area Under the Curve (AUC) Figure 2
ROC Curve of the three scores about patients' attitude 
towards initiating insulin injection (A) and their intentions 
regarding insulin therapy (B) at baseline; ability of the ques-
tionnaire to predict type 2 diabetes patients' attitude and 
intentions regarding initiating insulin injection are deduced 
from the Area Under the Curve (AUC). AM, 'acceptance and 
motivation'; FC, 'fears and constraints'; RB, 'restraints and 
barriers'
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Table 2: Score distribution (± standard deviation) of each of the 
dimensions obtained from cross-sectional populations at 
baseline
Dimensions SHIP Oral study (N 
= 1,487)
SHIP Premix study 
(N = 1,141)
'Acceptance and 
motivation'
47.1 ± 25.3 62.5 ± 26.4
'Fears and 
constraints'
69.3 ± 24.9 58.2 ± 28.2
'Restraints and 
barriers'
35.5 ± 28.6 23.5 ± 25.4
Table 3: Internal consistency reliability of the SHIP© 
questionnaire dimensions at baseline, in SHIP Oral (N = 1,478a) 
and SHIP Premix (N = 1,130b) studies, as measured by 
Cronbach's alpha
Dimensions SHIP Oral study SHIP Premix study
'Acceptance and 
motivation'
0.82 0.81
'Fears and 
constraints'
0.77 0.79
'Restraints and 
barriers'
0.78 0.74
a N = 1,487-9 due to missing data
b N = 1,141-11 due to missing dataHealth and Quality of Life Outcomes 2007, 5:53 http://www.hqlo.com/content/5/1/53
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recently diagnosed, and progressively decreased as the
time since diagnosis increased. 'Fears and constraints' and
'restraints and barriers' scores did not show significant dif-
ferences. When observed according to HbA1c dosage,
none of the 3 dimension scores showed significant differ-
ences. 'Acceptance and motivation' scores were directly
correlated to the answer given by patients about their
intention regarding initiating insulin injections: as
patients motivation increased, so did scores (scores = 31
and 43 for patients who "would refuse" and who "would
be rather reluctant", respectively; scores = 67 to 75 for
patients "quite motivated" to "highly motivated"). On the
other hand, 'fears and constraints' and 'restraints and bar-
riers' scores significantly decreased as patients' motivation
increased (scores = 75 and 46 for patients who answered
they "would refuse" to start injections; scores = 50 and 19
for "highly motivated" patients; p < 0.0001).
In the SHIP Premix study, 'acceptance and motivation'
scores were significantly different according to patients'
age, with the lowest score displayed by the youngest and
oldest patients (i. e. 59 for < 40 years-old patients and 60
for > 70 years-old; p = 0.023). 'Restraints and barriers'
scores were significantly (p < 0.0001) different between
age groups, and decreased with patients getting older. No
significant difference was observed for the 'fears and con-
straints' scores. When compared according to the type of
diabetes, type 1 patients had a lower 'acceptance and
motivation' score than type 2 diabetes patients (scores of
59 versus 64, respectively; p = 0.01). On the other hand,
'restraints and barriers' scores were higher for type 1 dia-
betes patients than for type 2 (p < 0.0001; scores of 29 ver-
sus 22). 'Fears and constraints' and 'restraints and barriers'
scores significantly (p < 0.05) increased for patients who
talked about insulin therapy with their physicians ('fears
and constraints' and 'restraints and barriers' to injection
scores = 57 and 21, respectively, for patients whose physi-
cians never talked to them about insulin therapy; scores =
61 and 27, respectively for patients whose physicians
talked to them several times). 'Acceptance and motiva-
tion' scores were not significantly different (p = 0.0916).
None of the three scores showed significant difference
when compared to the groups based on HbA1 dosage. As
in the SHIP Oral study, when compared to patients'
responses to the item on intention regarding injection
intensification, the 'acceptance and motivation' score was
directly correlated to patients' level of motivation: the
higher the patients' motivation, the higher the scores
(scores = 33 and 48 for patients who "would refuse" and
who "would be rather reluctant", respectively; scores = 72
to 81 for patients "quite motivated" to "highly moti-
vated"; p < 0.0001). On the contrary, scores of 'fears and
constraints' and 'restraints and barriers' to insulin therapy
were inversely correlated: the lower the patients' motiva-
tion, the higher the score (scores = 71 and 34, respectively,
for patients who answered they "would refuse" to start
injections; scores = 42 and 18 for "highly motivated"
patients; p < 0.0001).
Discussion
The SHIP© questionnaire was developed in order to assess
and predict patients' attitude, intentions and actual
change in treatment regimen regarding insulin injection
initiation/intensifications by identifying and evaluating
factors defining patients' perception, both positive and
negative, of insulin therapy and insulin injections in par-
ticular.
The questionnaire is concise, containing 14 items grouped
into 3 dimensions that cover 'acceptance and motivation'
(5 items), 'fears and constraints' (5 items), and 'restraints
and barriers' (4 items). One item asked patients to indi-
cate the 5 items they found the most important out of the
14 previously answered items. Two additional items eval-
Table 4: Predictive power measured by the AUC of each dimension scores of the questionnaire in the SHIP Oral and SHIP Premix 
studies for patients' attitude and actual choice and behavioural intentions regarding insulin therapy
SHIP Oral study/SHIP Premix study
Dimensions Clinician actual treatment decision regarding insulin initiation/
Intensification
Patients' intention regarding
insulin injection 
initiation/
intensification
inhaled insulin 
initiation/
intensification
Inclusion 6 months 12 months Inclusion Inclusion
'Acceptance and 
motivation'
0.80/0.65 0.65/0.64 0.59/0.64 0.86/0.86 0.65/0.72
'Constraints and fears' 0.72/0.62 0.58/0.61 0.56/0.60 0.75/0.78 0.60/0.68
'Restraints and 
barriers'
0.62/0.58 0.59/0.60 0.58/0.61 0.72/0.65 0.57/0.63Health and Quality of Life Outcomes 2007, 5:53 http://www.hqlo.com/content/5/1/53
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uated patients' intentions regarding insulin initiation or
intensification, either injected or inhaled. The develop-
ment of the questionnaire followed a standardised and
rigorous methodology [26,27], which ensured its good
content and construct validity and its good acceptability.
Item convergent and discriminant validity were satisfac-
tory for all items, indicating that each of them assessed the
concept of its own dimension without redundancy
between dimensions. Internal consistency reliability of
the dimensions proved to be excellent. The questionnaire
showed good correlations but no redundancy between the
concepts measured and the fear of self-injecting factor of
D-FISQ [28]. Lastly, the SHIP© questionnaire showed abil-
ity to predict patients' intentions regarding insulin ther-
apy as well as their actual change in treatment regimen, in
the SHIP Oral study and to a lesser extent, in the SHIP
Premix study.
Overall, the more recently diagnosed the diabetes, the
more motivated the patients are to initiate insulin injec-
tions. Among them, men were more motivated than
women, consistent with the higher level of restraints, fears
and constraints that women referred to when facing such
treatment. This suggested that women are probably more
concerned than men about the image they give of them-
selves to others. Patient motivation and acceptance of the
treatment were consistent with their attitude towards
insulin injections, i.e. motivated patients presenting low
restraints and fears had the highest positive attitude
towards such treatment.
As expected, patients who were already receiving insulin
injections were in large majority less reluctant to increase
the number of injections than patients who were receiving
treatment orally (70% versus 37%). This observation was
directly reflected by the higher proportion of patients
already treated by insulin injections who did indeed
undergo insulin injection intensification compared to
patients orally treated who did not initiate insulin injec-
tion, regardless the time of the study (13% versus 2% at
baseline; 16% versus 8% after 6 months, 16% versus 12%
after 12 months). These orally treated patients were highly
concerned about the fears and constraints related to insu-
lin injections, with 13% of them reporting they would be
worried that their diabetes would get worse, that they
would have more hypoglycaemic incidents, that they
would feel more dependent, or that their treatment would
get more complicated. Although to a lesser extent, same
reasons were reported by patients who would later agree
to increase the number of insulin injections. Similarly,
twice more patients already treated with insulin injection
would agree to increase their treatment if inhaled insulin
was available, compared to patients treated with OHA
(37% versus 17%, respectively).
Interestingly, in the SHIP Oral study, the 3 dimensions of
the questionnaire were predictive of patients' intentions
regarding insulin: the more motivated the patients and
the lower their fears and the barriers, the less reluctant the
patients were to initiate insulin injection. In the same way,
at baseline, the level of motivation and fears predicted the
intentions of patients already treated with insulin injec-
tions regarding an increased number of injections. In the
SHIP Premix study, the questionnaire was not predictive
of patients who actually underwent an increased number
of injections. Restraints and barriers were good predictive
criteria of patients' intentions regarding initiation of insu-
lin injections but in contrast, could not predict their inten-
tions regarding treatment intensification. One could
propose that at the inclusion visit, patients who were
ROC Curve of the three scores about patients' attitude  towards intensifying insulin injection (A) and their intentions  regarding insulin therapy (B) at baseline; ability of the ques- tionnaire to predict patients' attitude and intentions regard- ing intensifying insulin injection are deduced from the Area  Under the Curve (AUC) Figure 3
ROC Curve of the three scores about patients' attitude 
towards intensifying insulin injection (A) and their intentions 
regarding insulin therapy (B) at baseline; ability of the ques-
tionnaire to predict patients' attitude and intentions regard-
ing intensifying insulin injection are deduced from the Area 
Under the Curve (AUC). AM, 'acceptance and motivation'; 
FC, 'fears and constraints'; RB, 'restraints and barriers'
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already convinced or were about to be convinced, were
highly motivated to start/intensify insulin injection; on
the contrary, patients who were the most worried about
insulin treatment were not motivated, and indeed did not
start/intensify insulin injections, and required more inter-
actions with their physicians. That is, in order for patients
to change to and fully accept a new treatment, the most
important concern is for them to be convinced. At 6- and
12-month visits, patients have had time to think about
insulin injection treatment and be "mentally prepared"
for it. Thus, patients' responses at baseline no longer
reflect their actual state of mind 6 or 12 months later. Fur-
thermore, patients' medical status may have evolved,
resulting in a physician's decision that differs from
patients' intentions at their first visit. The 'restraints and
barriers' dimension was not predictive of the treatment
eventually administered, even at baseline. This further
confirmed that in order to trigger patient decision, physi-
cians should particularly insist on the positive aspects of
an efficient treatment, as patients essentially need to be
convinced. The slightly higher predictive ability of the
questionnaire in the SHIP Premix study compared to that
in the SHIP Oral study could be explained by the fact that
patients who receive insulin injections are already familiar
with this mode of administration; in contrast, patients in
the SHIP Oral study are insulino-naïve, and therefore lack
information about the advantages and inconveniencies of
such treatment.
Altogether, these observations on patient attitude, inten-
tions, and behaviour towards insulin treatment follow
and share features of the Theory of Planned Behaviour
model, a theory from social psychology field [35-37].
According to this theory, behavioural intention is a good
proximal measure of actual behaviour, and in order to
predict a person's behavioural intention, information on
'attitude' (i.e. whether a person is in favour of doing 'it'),
'subjective norms' (i.e. how much a person feels social
pressure to do 'it') and 'perceived behavioural control'
(i.e. whether the person feels in control of the action) is
required. By allowing this information to be assessed, the
SHIP© questionnaire provides good basis for further iden-
tifying how patients' management at an individual or col-
lective level could help to influence their behaviour, as
well as for facilitating clinicians' decision to switch a
patient's treatment to insulin or to increase insulin doses
whenever required. The impact of its use to support
improved communication and care needs to be evaluated
in a specific study.
Concerning inhaled insulin, the SHIP© questionnaire did
not demonstrate convincing findings in its ability to help
predict patients' intentions in any of the studies. However,
as already observed in previous work [17], it is interesting
to note that patients, regardless of their type of diabetes
and insulin therapy, would be very much in favour of
inhaled insulin if this were available.
Conclusion
The design of this present study (i.e. large population
samples and long time period), the rigorous methodology
used to develop the questionnaire, the characteristics of its
structure and clinical content, and the properties of the
instrument make the SHIP© questionnaire a good candi-
date for further validation of its use in clinical practice.
Larger studies with specific population settings and real-
life studies will be useful to validate and confirm its place
in everyday and clinical practice [38].
The SHIP© questionnaire is a reliable and valid instrument
that is promising for assessing the intentions of type 1 and
type 2 diabetes patients regarding insulin therapy, and the
reasons for their behaviour. The questionnaire demon-
strates ability to predict actual change in treatment regi-
men in the short term, and confirms the importance of
patient-physician communication in treatment decision
in diabetes. The SHIP© questionnaire would thus be a
helpful tool for physicians to interact and communicate
with their patients.
Copyrights
The SHIP© questionnaire is protected by copyright with all
rights reserved by Pfizer. Do not use without permission.
For information on, or permission to use the USP©, please
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